A
Asha Krishnan
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 8
Citations - 965
Asha Krishnan is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Colorectal cancer & Medicine. The author has an hindex of 3, co-authored 6 publications receiving 466 citations. Previous affiliations of Asha Krishnan include NorthShore University HealthSystem.
Papers
More filters
Journal ArticleDOI
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Scott Kopetz,Axel Grothey,Rona Yaeger,Eric Van Cutsem,Jayesh Desai,Takayuki Yoshino,Harpreet Wasan,Fortunato Ciardiello,Fotios Loupakis,Yong Sang Hong,Neeltje Steeghs,Tormod Kyrre Guren,Hendrik Tobias Arkenau,Pilar García-Alfonso,Per Pfeiffer,Sergey Orlov,Sara Lonardi,Elena Elez,Tae Won Kim,Jan H.M. Schellens,Christina Guo,Asha Krishnan,Jeroen Dekervel,Van Morris,Aitana Calvo Ferrándiz,Line Schmidt Tarpgaard,Michael Braun,Ashwin Gollerkeri,Christopher Hunt Keir,Kati Maharry,Michael D Pickard,Janna Christy-Bittel,Lisa Anderson,Victor Sandor,Josep Tabernero +34 more
TL;DR: A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the BRAF V600E mutation.
Journal ArticleDOI
Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy.
Andrea Cercek,Gustavo Dos Santos Fernandes,Campbell S.D. Roxburgh,Karuna Ganesh,S.Y. Ng,Francisco Sanchez-Vega,Rona Yaeger,Neil H. Segal,Diane Reidy-Lagunes,Anna M. Varghese,Arnold J. Markowitz,Chao Wu,Bryan C. Szeglin,Charles-Etienne Gabriel Sauve,Erin E. Salo-Mullen,Christina Tran,Zalak Patel,Asha Krishnan,Kaitlyn Tkachuk,Garrett M. Nash,Jose G. Guillem,Philip B. Paty,Jinru Shia,Nikolaus Schultz,Julio Garcia-Aguilar,Luis A. Diaz,Karyn A. Goodman,Leonard B. Saltz,Martin R. Weiser,J. Joshua Smith,Zsofia K. Stadler +30 more
Abstract: Purpose: Evaluate response of mismatch repair–deficient (dMMR) rectal cancer to neoadjuvant chemotherapy. Experimental Design: dMMR rectal tumors at Memorial Sloan Kettering Cancer Center (New York, NY) were retrospectively reviewed for characteristics, treatment, and outcomes. Fifty patients with dMMR rectal cancer were identified by IHC and/or microsatellite instability analysis, with initial treatment response compared with a matched MMR-proficient (pMMR) rectal cancer cohort. Germline and somatic mutation analyses were evaluated. Patient-derived dMMR rectal tumoroids were assessed for chemotherapy sensitivity. Results: Of 21 patients receiving neoadjuvant chemotherapy (fluorouracil/oxaliplatin), six (29%) had progression of disease. In comparison, no progression was noted in 63 pMMR rectal tumors (P = 0.0001). Rectal cancer dMMR tumoroids reflected this resistance to chemotherapy. No genomic predictors of chemotherapy response were identified. Of 16 patients receiving chemoradiation, 13 (93%) experienced tumor downstaging; one patient had stable disease, comparable with 48 pMMR rectal cancers. Of 13 patients undergoing surgery, 12 (92%) had early-stage disease. Forty-two (84%) of the 50 patients tested positive for Lynch syndrome with enrichment of germline MSH2 and MSH6 mutations when compared with 193 patients with Lynch syndrome–associated colon cancer (MSH2, 57% vs 36%; MSH6, 17% vs 9%; P Conclusions: Over one-fourth of dMMR rectal tumors treated with neoadjuvant chemotherapy exhibited disease progression. Conversely, dMMR rectal tumors were sensitive to chemoradiation. MMR status should be performed upfront in all locally advanced rectal tumors with careful monitoring for response on neoadjuvant chemotherapy and genetic testing for Lynch syndrome in patients with dMMR rectal cancer.
Journal ArticleDOI
A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers.
Andrea Cercek,Walid K. Chatila,Walid K. Chatila,Rona Yaeger,Henry Walch,Gustavo Dos Santos Fernandes,Asha Krishnan,Lerie Palmaira,Anna Maio,Yelena Kemel,Preethi Srinivasan,Chaitanya Bandlamudi,Erin E. Salo-Mullen,Prince Rainier Tejada,Kimeisha Belanfanti,Jesse Galle,Vijai Joseph,Neil H. Segal,Anna M. Varghese,Diane Reidy-Lagunes,Jinru Shia,Efsevia Vakiani,Sebastian Mondaca,Robin B. Mendelsohn,Melissa Lumish,Felix Steinruecke,Nancy E. Kemeny,Louise Catherine Connell,Karuna Ganesh,Arnold J. Markowitz,Garrett M. Nash,Jose G. Guillem,J. Joshua Smith,P. Paty,Liying Zhang,Diana Mandelker,Ozge Birsoy,Mark E. Robson,Kenneth Offit,Barry S. Taylor,Michael F. Berger,David B. Solit,Martin R. Weiser,Leonard B. Saltz,Julio Garcia Aguilar,Nikolaus Schultz,Luis A. Diaz,Zsofia K. Stadler +47 more
TL;DR: In this article, the authors compared the early-onset colorectal cancer (EO-CRC) incidence with the AO-carcinogenesis (AO-Carc) and found no statistically significant differences at the gene or pathway level.
Journal ArticleDOI
Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis
TL;DR: A weak association between new-onset IBD and TNF-α inhibitor therapy in RA patients and a moderately strong association especially with etanercept exposure in JRA patients was observed, but causality cannot be determined due to limitations of the FAERS and the Naranjo score.
Journal ArticleDOI
PD-1 blockade in solid tumors with defects in polymerase epsilon.
Benoit Rousseau,Ivan Bièche,Eric Pasmant,Nadim Hamzaoui,Nicolas Leulliot,Lucas Michon,Aurélien de Reyniès,Valéry Attignon,Michael B. Foote,Julien Masliah-Planchon,Magali Svrcek,Romain Cohen,Victor Simmet,Paule Augereau,David Malka,Antoine Hollebecque,Damien Pouessel,Carlos Gomez-Roca,Rosine Guimbaud,Amandine Bruyas,Marielle Guillet,Jean-Jacques Grob,Muriel Duluc,Sophie Cousin,Christelle De La Fouchardiere,Aude Flechon,Frederic Rolland,Sandrine Hiret,Esma Saada-Bouzid,Olivier Bouché,Thierry André,Diane Pannier,Farid El Hajbi,Stéphane Oudard,Christophe Tournigand,Jean-Charles Soria,Stéphane Champiat,Drew G. Gerber,Dennis Stephens,Michelle F. Lamendola-Essel,Steven Brad Maron,Bill H. Diplas,Guillem Argiles,Asha Krishnan,Séverine Tabone-Eglinger,Anthony Ferrari,Neil H. Segal,Andrea Cercek,N. Hoog-Labouret,Frederic Legrand,Clotilde Simon,Assia Lamrani-Ghaouti,Luis A. Diaz,Pierre Saintigny,Sylvie Chevret,Aurélien Marabelle +55 more
TL;DR: This study illustrates how specific DNA repair defects can sensitize to immunotherapy, POLE proofreading deficiency representing a novel tumor agnostic biomarker for response to PD-1 checkpoint blockade therapy.